FREEHOLD, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and laboratory services, today announced the launch of the "BrAce for Impact" affiliate marketing program for KetoAir™, a handheld breathalyzer device equipped with AI-enabled software and Hot App shareable technology, specifically designed for ketogenic health... Read More

FREEHOLD, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and laboratory services, today announced that it has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board. Dr. Charles Cavo is the co-founder and Chief Medical Officer of Pounds Transformation, founded to help patients successfully reach... Read More

FREEHOLD, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and laboratory services, today announced that it entered into a memorandum of understanding (the “MOU”) with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to... Read More

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and laboratory services, today announced that it will effect a 1-for-15 reverse split (“reverse split”) of its common shares that will become effective on October 28, 2024. The Company expects that the reverse stock split will allow the Company to regain... Read More

FREEHOLD, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and laboratory services, today announced its participation as an event sponsor at the Keto Pa-LOU-za 2024 Conference, taking place October 11-13, 2024, at the Galt House Hotel in Louisville, KY. Avalon will use the event to showcase the KetoAir™ breathalyzer... Read More

FREEHOLD, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC (“LSM”) has begun manufacturing the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontinence device. LSM plans to launch its sales of... Read More

FREEHOLD, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC (“LSM”) has launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependence. To purchase or find out... Read More

FREEHOLD, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of online sales for the KetoAir™ breathalyzer device and related accessories in the U.S. The products are now available at www.ketoair.us . KetoAir™ is a breathalyzer featuring Hot... Read More

FREEHOLD, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today provided an update on the launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference that was held on May 31 to June 2, 2024 in Austin,... Read More

FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it received a notice (the “Notice”) on May 22, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirements for continued listing under... Read More

FREEHOLD, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference being held from May 31 to June 2, 2024 in Austin, Texas.... Read More

FREEHOLD, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, is pleased to announce the extension of its exclusive distribution agreement with Qi Diagnostics Limited (“Qi Diagnostics”) to distribute the KetoAir™, a breathalyzer device and related accessories, including current... Read More

FREEHOLD, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that it engaged ChtrBx , a marketing and branding company, to develop a marketing launch plan for KetoAir™ in North America, South America, the United Kingdom (UK) and the European Union (EU). In... Read More

FREEHOLD, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that it has partnered with Qi Diagnostics Limited (“Qi Diagnostics”) to co-develop international multi-center clinical studies for DKAir™ breathalyzer device for the early detection of diabetic... Read More

KetoAir™ Mobile Application Launches in Apple App Store KetoAir™ Mobile Application also Available in the Google Play Store FREEHOLD, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced the launch of the KetoAir™ mobile application in the Apple App store. The... Read More

FREEHOLD, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired Merlin Medical Supply (“MMS”), a profitable, well-established Home Medical Equipment (“HME”) and Durable Medical Equipment (“DME”) company providing... Read More

FREEHOLD, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Publication for U.S. Patent No. 11,555,060, titled “QTY Fc Fusion Water Soluble Receptor Proteins.” The publication... Read More

New Proprietary Testing Method Makes Tuberculosis Diagnosis Easier and Faster New Test Method Expected to Generate Revenue in 2023 FREEHOLD, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that Laboratory Services MSO, LLC (“LSM”) is now offering an in-house... Read More

New Wholly Owned Lab “Veritas Laboratory” of Arizona, Anticipated to Generate Revenue in 2023 Engages Former Congressman Barry M. Goldwater Jr. To Expand Insurance Coverage and Grow Lab Footprint FREEHOLD, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced... Read More

FREEHOLD, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired DE Laboratory LLC (“DE Labs”), which expands its penetration within Texas and provides significant potential growth opportunities for the combined... Read More

MSA Signed with GeneX Laboratory, an In-Network Laboratory Licensed in Multiple States Including Medicare and Medicaid Laboratory Services MSO will be the Exclusive Testing Provider for Toxicology Testing, Genetic Testing and Others FREEHOLD, N.J., July 19, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical... Read More

Company Continues to Implement Major Change in Strategy Focused on Acquiring and Operating Accretive Revenue Generating Laboratories and Related Commercialized Products Company Plans on Developing and Delivering Innovative, Transformative, Precision Diagnostics, Genetic Testing and Clinical Laboratory Services FREEHOLD, N.J., July 10, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT)... Read More

FREEHOLD, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today reported financial results for Laboratory Services MSO, LLC (“LSM”) for the twelve months ended December 31, 2022. In February 2023, Avalon acquired a 40% interest in LSM, a premier clinical diagnostics and... Read More

FREEHOLD, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the commercial launch of the KetoAir™ breathalyzer device and related accessories at the KetoCon Austin 2023 conference, which is being held on April 21-23, 2023 in Austin, Texas. Avalon will showcase... Read More

Commercialization-ready; initially targeting diabetes reversal and weight management markets Coupling diagnostic tools with advanced artificial intelligence software for nutrition management FREEHOLD, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it... Read More

FREEHOLD, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has been invited to participate in the 35 th Annual Roth Conference being held on March 13 and 14, 2023. Luisa Ingargiola, Chief Financial Officer of Avalon, will be available... Read More

Transaction Expected to Be Accretive to Earnings Through Profit Sharing Agreement Adds Strong Clinical Synergies to Existing Avalon Portfolio Marks Launch of New Roll-Up Strategy Targeting Toxicology and Pharmacogenetic Laboratories FREEHOLD, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a leading global developer of innovative cell-based technology, cellular... Read More